Microsoft Corporation is upgraded to Buy due to a strong moat and revenue growth with a 36% upside to $545 fair value. Read ...
NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis. NICE has said Biogen's Tysabri can now be used by the NHS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results